BCRX - BioCryst Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.05
+0.17 (+2.47%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.88
Open6.91
Bid0.00 x 3000
Ask0.00 x 800
Day's Range6.68 - 7.06
52 Week Range3.95 - 7.49
Volume477,459
Avg. Volume841,246
Market Cap771.143M
Beta2.17
PE Ratio (TTM)N/A
EPS (TTM)-0.83
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.25
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    New Research Coverage Highlights Cincinnati Bell, BioCryst Pharmaceuticals, Shutterstock, Kopin, Lands' End, and Pieris Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cincinnati ...

  • BioCryst banks gross proceeds of $57.5M from offering
    American City Business Journals9 days ago

    BioCryst banks gross proceeds of $57.5M from offering

    BioCryst (Nasdaq: BCRX) has raised $57.5 million in a public offering of its common stock, according to the company, with the underwriters’ option to purchase additional shares exercised in full. BioCryst, based in Research Triangle Park, said Monday that the company has been granted Fast Track Designation by the U.S. Food and Drug Administration for its product to prevent angioedema attacks in patients with hereditary angioedema, or HAE. Proceeds of the company’s public offering will be used for further development of that product candidate – known as BCX7353 – as well as for other corporate purposes, according to BioCryst.

  • BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks10 days ago

    BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

    BioCryst (BCRX) delivered earnings and revenue surprises of 17.39% and 228.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press10 days ago

    BioCryst: 2Q Earnings Snapshot

    On a per-share basis, the Durham, North Carolina-based company said it had a loss of 19 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire10 days ago

    BioCryst Reports Second Quarter 2018 Financial Results

    RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018-- BioCryst Pharmaceuticals, Inc. announced today financial results for the second quarter ended June 30, 2018.. “Building on the clear direction from our shareholders ...

  • GlobeNewswire10 days ago

    BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

    BioCryst Pharmaceuticals, Inc. (BCRX) announced today the completion of an underwritten public offering of 10,454,546 shares of its common stock, including 1,363,636 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. The gross proceeds from this offering to BioCryst, including from the shares sold pursuant to the underwriters’ option to purchase additional shares, were approximately $57.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by BioCryst.

  • BioCryst gets FDA nod on key drug
    American City Business Journals11 days ago

    BioCryst gets FDA nod on key drug

    A key drug for BioCryst Pharmaceuticals (Nasdaq: BCRX) is now on the fast track, according to the U.S. Food and Drug Administration amid its shift to a standalone strategy. BioCryst, based in Research Triangle Park, said Monday that it has been granted Fast Track Designation by the FDA for a product designed to prevent angioedema attacks in patients with hereditary angioedema.

  • GlobeNewswire11 days ago

    U.S. FDA Grants Fast Track Designation for BioCryst’s BCX7353

    BioCryst Pharmaceuticals, Inc. (BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the Company has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for BCX7353 for the prevention of angioedema attacks in patients with hereditary angioedema (HAE). Fast Track Designation provides opportunities for frequent interactions with the FDA during development of a product candidate and provides the opportunity for priority review if supported by clinical data at the time of the new drug application (NDA) submission.

  • After Idera deal called off, BioCryst looks to raise $50M
    American City Business Journals14 days ago

    After Idera deal called off, BioCryst looks to raise $50M

    Less than a month after shareholders of Research Triangle Park-based BioCryst Pharmaceuticals blocked the company’s proposed merger with Exton, Pennsylvania-based Idera Pharmaceuticals, BioCryst is looking to raise $50 million in a public offering of the company’s common stock.  BioCryst (Nasdaq: BCRX) has priced a public offering of about 9 million shares of its common stock at $5.50 per share. It has also granted underwriters a 30-day option to purchase up to about 1.4 million additional shares.  The company recently initiated a Phase 3 clinical trial of its lead drug candidate BCX7353 for the treatment of hereditary angioedema (HAE).

  • Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today
    Motley Fool15 days ago

    Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today

    Investors are cheering the orphan drug specialist's decision to raise a nice chunk of capital via a public offering.

  • Benzinga15 days ago

    The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 1) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CAS Medical Systems ...

  • GlobeNewswire15 days ago

    BioCryst Pharmaceuticals Prices Public Offering of Common Stock

    BioCryst Pharmaceuticals, Inc. (BCRX) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock, offered at a price to the public of $5.50 per share.  The gross proceeds from this offering to BioCryst are expected to be $50 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioCryst.  BioCryst has granted the underwriters a 30-day option to purchase up to an additional 1,363,636 shares of its common stock.  The offering is expected to close on or about August 6, 2018, subject to customary closing conditions.

  • GlobeNewswire15 days ago

    BioCryst Pharmaceuticals Commences Public Offering of Common Stock

    BioCryst Pharmaceuticals, Inc. (BCRX) a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that it is offering to sell $50 million of its common stock in an underwritten public offering. As part of this offering, BioCryst intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of its common stock. J.P. Morgan and Jefferies are acting as joint book-running managers for the proposed offering.

  • GlobeNewswire21 days ago

    BioCryst to Announce Second Quarter 2018 Financial Results on August 7

    RESEARCH TRIANGLE PARK, N.C., July 27, 2018-- BioCryst Pharmaceuticals, Inc. announced today that its second quarter 2018 financial results will be reported on Tuesday, August 7, 2018.. BioCryst will host ...

  • GlobeNewswire22 days ago

    BioCryst Announces Publication of APeX-1 Clinical Trial Results for BCX7353 in The New England Journal of Medicine

    BioCryst Pharmaceuticals, Inc. (BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that results from the Phase 2, APeX-1 clinical trial of BCX7353 for the prevention of attacks in patients with hereditary angioedema (“HAE”) are published online in the July 26th issue of The New England Journal of Medicine (DOI: 10.1056/NEJMoa1716995). The trial demonstrated that oral administration of BCX7353 at a dose of 125 mg or more resulted in a significantly lower rate of attacks compared with placebo. Mild gastrointestinal symptoms were the principal side effect, particularly in the 250 mg and 350 mg BCX7353 dose groups.

  • ACCESSWIRE24 days ago

    Stock Performance Review on AVEO Pharma and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on AVEO sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...

  • Why American Airlines, Idera Pharmaceuticals, and RH Holdings Slumped Today
    Motley Foollast month

    Why American Airlines, Idera Pharmaceuticals, and RH Holdings Slumped Today

    From a scuttled merger to tariff troubles, see why shares of these three companies fell hard today.

  • Why Idera Pharmaceuticals Is Sinking Today
    Motley Foollast month

    Why Idera Pharmaceuticals Is Sinking Today

    Shares plunge after its proposed merger is called off. Here's what investors need to know.

  • Spurned at the altar: BioCryst shareholders reject merger with Exton's Idera Pharmaceuticals
    American City Business Journalslast month

    Spurned at the altar: BioCryst shareholders reject merger with Exton's Idera Pharmaceuticals

    Idera shareholders voted in favor of the deal. The Chester County company will get $6M as a result of the termination.

  • Future of Idera's Cambridge office uncertain after failed merger
    American City Business Journalslast month

    Future of Idera's Cambridge office uncertain after failed merger

    The Cambridge-based immunology biotech's future is murky after a planned merger with drug developer BioCryst fell through this week.

  • The Wall Street Journallast month

    Stocks to Watch: Boeing, Ford, American Airlines, JetBlue, Pfizer, Comcast, Alphabet, Nvidia, AbbVie

    Among the companies with shares expected to trade actively in Wednesday's session are Boeing, Ford, American Airlines, Pfizer and Comcast.

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 10) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioXcel Therapeutics ...

  • Business Wirelast month

    BioCryst Provides Update on Strategy, Pipeline and Outlook

    BioCryst Pharmaceuticals, Inc. (BCRX) (“BioCryst” or the “Company”), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today provided an update on the Company’s strategic and financial outlook as a standalone company following the recent termination of its merger agreement with Idera Pharmaceuticals, Inc. (IDRA) (“Idera”). Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, said, “We are moving forward executing our standalone strategy with a great deal of confidence in our programs, our pipeline and our ability to drive value for our stockholders. Also, we are on track for a first half of 2019 initiation of a Phase 1 clinical trial for our ALK-2 inhibitor program for treating fibrodysplasia ossificans progressiva, or FOP.

  • No deal: BioCryst shareholders thwart merger with Idera
    American City Business Journalslast month

    No deal: BioCryst shareholders thwart merger with Idera

    There will be no deal as shareholders of Research Triangle Park-based BioCryst Pharmaceuticals have blocked the company’s proposed merger with Exton, Pennsylvania-based Idera Pharmaceuticals.